12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. It has also received accelerated approval for treatment of adults and pediatric (⩾age 12 years) patients with metastatic Merkel cell carcinoma. 5 Preclinical development and pharmacokinetics of avelumab Avelumab selectively blocks the interaction between programmed cell-death 1 (PD-1) and B7.1 (PD-L1) receptors, while still allowing interaction between PD-L2 and PD-1. 5 This interaction then allows T-cell receptor activation and cell lysis. In vitro studies have shown that avelumab can lyse a range of human tumor cells in the presence of peripheral blood mononuclear cells consistent with this mechanism of action. [6] [7] [8] [9] Unlike currently available anti-PD-1 antibodies, avelumab's IgG1 Fc portion can bind Fc receptors to activate antibody-mediated cytotoxicity (ADCC). Indeed, preclinical data show that avelumab leads to potent cell killing in the presence of natural killer (NK) cells purified from either healthy donors or cancer patients. [7] [8] [9] [10] [11] ADCC has been demonstrated in several in vitro models, potentially suggesting two nonoverlapping mechanisms of action. 6, 8 The pharmacokinetics of avelumab was studied in the JAVELIN solid tumor trial, a phase I trial with patients receiving doses ranging from 1 to 20 mg/kg every 2 weeks. 12, 13 The exposure of avelumab increased dose proportionally in the dose range of 3 to 20 mg/kg every 2 weeks. For all doses, the mean time to maximum concentration was within 1 h from the end of infusion. Steadystate concentrations of avelumab were reached after approximately 4 to 6 weeks (two to three cycles) of repeated dosing. Avelumab was primarily eliminated via proteolytic degradation and the terminal half-life was 6.1 days in patients receiving 10 mg/kg. No clinically meaningful differences in pharmacokinetics were observed for avelumab based on age, sex; mild, moderate or severe renal impairment (creatinine clearance 30 to 89 ml/min); and mild or moderate hepatic impairment [bilirubin less than or equal to three times the upper limit of normal (ULN)]. There are inadequate data for patients with severe hepatic impairment (bilirubin greater than three times ULN).
Clinical investigation of avelumab in bladder cancer
The above-mentioned JAVELIN trial [Clinical Trials.gov identifier: NCT01772004] was the pivotal trial examining the role of avelumab in locally advanced or metastatic UC. Adult patients with histologically confirmed locally advanced or metastatic UC were enrolled in two sequential cohorts: an initial cohort and an efficacy expansion cohort. Eligible patients were required to have disease progression after at least one previous platinum-based chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
A pooled analysis of the patients in the UC cohorts of this trial was recently published. 13 A total of 249 patients were enrolled including 58 (23%) with upper tract (renal pelvis or ureter) and 191 (77%) with lower tract (bladder or urethra) tumors. Only 13 (5%) patients were cisplatin ineligible. Of the 206 patients evaluable for PD-L1 expression level, 82 (33%) had PD-L1-positive tumors and 124 (50%) had PD-L1-negative tumors. Patients received avelumab 10 mg/kg by 1-h intravenous (IV) infusion every 2 weeks until the occurrence of disease progression, unacceptable toxicity, or other protocolspecified criteria for withdrawal. Median duration of treatment was 12.0 weeks [interquartile range (IQR) 6.0-19.7] and median follow up was 9.9 months (4.3-12.1). Objective response rate (ORR) was 17% [95% confidence interval (CI) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , including nine (6%) complete responses and 18 (11%) partial responses by RECIST criteria. The disease control rate (proportion of patients with a complete response, partial response or stable disease) was 40% (64 of 161 patients). Median progression-free survival (PFS) was 6.3 weeks (95% CI 6.0-10.1). In patients with a confirmed response, median time to response was 11.4 weeks (IQR 5.9-17.4) and median duration of response was not reached by data cutoff (95% CI 42.1 weeks to not estimable). Most common reason for treatment discontinuation was disease progression, seen in 125 (50%) patients. Only 50 (20%) of 249 patients received anticancer treatment after discontinuing avelumab, including cytotoxic chemotherapy in 39 (16%) patients, kinase inhibitor in five (2%), antibody therapy in five (2%), and hormonal therapy in one (<1%). Median overall survival (OS) was 6.5 months (95% CI 4.8-9.5), and the 6-month OS rate was 53% (45-60).
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Adverse event profile of avelumab
In the pooled analysis, adverse events of any grade occurred in 244 (98%) of 249 patients, including in 166 (67%) who had a treatment-related adverse event (TRAE). The most frequent TRAEs of any grade were infusion-related reaction (IRR) in 73 (29%) patients, and fatigue in 40 (16%) patients. All IRRs were grade ⩽ 2 and occurred mostly during the first or second infusions. Only 21 (8%) of 249 patients had grade 3 or worse TRAEs, the most common of which were four with fatigue (2%), asthenia, elevated lipase, hypophosphataemia, and pneumonitis in two (1%) patients each. There were three grade 4 TRAE (elevated lipase and creatine phosphokinase concentrations, and hyperkalemia), and one treatment-related death, due to pneumonitis in a patient with ongoing treatment-unrelated Clostridium difficile colitis and diverticulitis. A total of 34 (14%) of 249 patients had immune-related adverse events (IRAE), mostly rash (n = 12; 10%) and hypothyroidism (n = 9; 4%). Avelumab was permanently discontinued after a TRAE in 14 (6%) patients: IRR and pneumonitis in two (1%) patients each, and adrenal insufficiency, acute kidney injury, arthralgia, diarrhea, raised concentrations of alkaline phosphatase, aspartate aminotransferase, gamma-glutamyl transferase and lipase, enterocolitis, fatigue, general physical health deterioration, Guillain-Barré syndrome, and rash in one (<1%) patient each.
Predictors for avelumab response
Tumor PD-L1 status: In the JAVELIN trial, a positive PD-L1 status was defined as >5% PD-L1 expression on tumor cells using the Dako PD-L1 IHC 73-10 pharmDx assay (Dako, Carpinteria, California, USA). A total of 206 patients were evaluable for PD-L1 expression level. Nonevaluable samples (n = 43) were those that were missing, of poor quality due to insufficient tumor content or cellular preservation, or otherwise not available to provide results. A sum of 82 (33%) patients were classified as PD-L1 positive and 124 (50%) patients as PD-L1 negative. A summary of responses and survival in evaluable patients is summarized in Table 1 .
Thus, similar to experience with other anti-PD-1/ PD-L1 agents in UC, there's a trend toward higher ORR and improved PFS and OS in patients with positive PD-L1 status with avelumab therapy. Generalizability of this data is limited due to use of different PD-L1 assays and cutoffs, as well as lack of longer-term survival data in the UC cohorts of the JAVELIN SOLID TUMOR trial.
Tumor mutational burden: Ribonucleic acid sequencing (RNAseq) of RNA extracted from archival slides was performed. Tumor-specific mutations were then identified by combining tumor RNASeq data with germline nontumor whole-exome sequencing. Resulting mutations were analyzed with NetMHCPan (http://www.cbs. dtu.dk/services/NetMHCpan-4.0) to predict peptide binding to major histocompatibility complex molecules of known sequences. Potential neoantigens were weighted based on expression level.
In 29 analyzed samples, an exploratory post hoc analysis did not reach statistical significance for the association between increased mutational load and improved antitumor response (p = 0.076, Wilcoxon rank sum test; sample size 29). These results are not conclusive due to small sample size and methodological limitations. Safety profile of avelumab also appears comparable with other immunotherapy agents in its class except for potentially higher (though only grade ⩽ 2) rates of infusion-related reactions. Grade 3 and grade 4 IRRs are rare with avelumab, occurring in 0.2% and 0.5% of all patients, respectively. In clinical trials, most patients received diphenhydramine (a first-generation antihistamine) and acetaminophen as a premedication, and the FDA avelumab prescribing information recommends this strategy for the first four infusions, to prevent IRR. The magnitude of benefit (IRR risk reduction) from this premedication regimen is not known for avelumab and this recommendation is based on the cumulative experience from other CPI therapies.
Management of IRRs is relatively straightforward: should a grade 1 or 2 IRR occur despite premedication, physicians can choose to either decrease the infusion rate, or interrupt and restart at a slower rate, in addition to administering supportive medications. Decreasing the dose of avelumab is not recommended, and treatment discontinuation is not required for grade ⩽ 2 IRRs. Grade 3 or 4 IRRs require immediate and permanent discontinuation of avelumab infusion, administration of IV corticosteroids and close observation. 15 Interestingly, avelumab has a shorter terminal half-life at 6.1 days compared with other CPIs (e.g. pembrolizumab, 26 days). 14 Whether this translates into a decreased frequency of late (⩾30 days after treatment discontinuation) IRAEs, or a shorter duration of systemic corticosteroid therapy for IRAE for avelumab-treated patients, is unknown.
Conclusions and future directions
It is clear from the above data that avelumab is an active agent in advanced UC. Avelumab is now available as a standard of care option for patients having failed one line of prior chemotherapy. However, pembrolizumab has an advantage over other CPIs including avelumab in this setting, as it is the only agent to have shown an OS benefit. 16 Avelumab is given every 2 weeks rather than every 3 or 4 weeks for the others, and this might be considered less convenient from a patient perspective.
For these reasons, several trials have been initiated to explore avelumab in other settings for UC such as combination chemoimmunotherapy for muscle-invasive UC before cystectomy and previously untreated metastatic UC. Numerous other trials are exploring avelumab in combination with other CPI, as well as potentially immunostimulatory or immunomodulating therapies such as PARP inhibitor or multikinase inhibitor. Table 2 has a listing of ongoing clinical trials which will include patients with UCs. While many of these studies are early-phase combination studies for all solid tumors, there are several studies specifically studying patients with UCs. The vast majority of these studies will be reporting results in 2019-2020. Whether or not avelumab will emerge from one of these studies as a clear winner remains to be seen.
Another interesting and perhaps unique approach is the creation of a fusion protein containing avelumab. One such first-in-class bifunctional fusion protein, M7824 (MSB0011359C), comprising an anti-PD-L1 moiety based on avelumab fused to the extracellular domain of human transforming growth factor beta (TGF-β) receptor 2 has shown remarkable preclinical activity. 17 A phase I clinical trial of this drug is currently ongoing and data from 19 heavily pretreated patients treated in the dose-escalation part was recently published. 18 The drug showed good desired endtarget activity, with saturation of peripheral PD-L1 and sequestration of any released plasma TGF-β1, -β2, and -β3 at doses higher than 1 mg/ kg. Side effects were manageable and maximally tolerated dose was not reached. There was early evidence of efficacy with one complete response (cervical cancer), two durable partial responses (PRs; pancreatic cancer and anal cancer), one near PR (cervical cancer). Enrollment in expansion cohorts is ongoing.
Given the breadth and depth of clinical and preclinical development, it is safe to say that avelumab is likely to have a continued role in the management of patients with UC.
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